ReviewReproduction (Cambridge, England)2025
POLYCYSTIC OVARY SYNDROME: ORIGINS AND IMPLICATIONS: Gestational anti-Müllerian hormone and testosterone excess combined with maternal adiposity program for polycystic ovary syndrome.
Review in Reproduction (Cambridge, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Endocrinological Basis for Polycystic Ovary Syndrome: An Evolutionary Perspective.Endocrinology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
In brief: A 'two hit' developmental origin involving testosterone and anti-Müllerian hormone is proposed to initiate PCOS pathogenesis during gestation. Epigenetic mechanisms amplify genetically heritable traits, while accompanying metabolic perturbations, including gestational hyperglycemia, hypertension and maternal obesity, exaggerate PCOS expression. Abstract: Pre- or perinatal excess of anti-Müllerian hormone (AMH) or testosterone faithfully reproduce many polycystic ovary syndrome (PCOS)-like reproductive and metabolic traits in animal models. Epigenetic transgenerational transmission of such developmental programming has been repeatedly demonstrated in mice and is likely to exist in nonhuman primates. In humans, hyperandrogenic PCOS is reliably heritable and repeatedly associated with >20 PCOS risk genes and altered epigenetic signatures. Infant daughters of women with PCOS exhibit traits consistent with a hyperandrogenic fetal environment that is accompanied by precocious onset of AMH hypersecretion. Elevated AMH levels, likely of ovarian origin, persist from birth through adolescence in daughters of women with PCOS, and in adult women with PCOS, and associate with extending the reproductive years and delaying peri-menopause. Evidence is accumulating for fetal extra-ovarian production and action of AMH in various tissues: the brain, for survival of GnRH neurons migrating from the embryonic nose to the hypothalamus; the pituitary, for gonadotrope development; and the placenta, for optimal fetal support. In addition, PCOS risk genes, including those regulating androgen biosynthesis, are being identified in many families with PCOS, bestowing the potential for intrinsic androgen excess in the fetal ovary, adrenal, brain, abdominal adipose and pilosebaceous glands. A 'two hit' developmental origin may therefore promote PCOS pathogenesis during gestation when epigenetic mechanisms amplify genetically heritable traits, while accompanying metabolic perturbations, including gestational hyperglycemia, hypertension and maternal obesity, may exaggerate the phenotypic expression of PCOS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.